TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS are included in this Analyst Blog. ... Tempus AI has skyrocketed 21% in the last three days, ...

Tempus AI said it will work with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology that can gather biological and clinical insights, discover novel drug targets and ...

Key Takeaways Tempus AI stock shows 15–32% upside potential based on analyst forecasts.The company leads in using artificial ...

Tempus AI will receive $200 million in data licensing and model development fees from AstraZeneca. This amount almost exactly matches the amount of revenue the company generated in the fourth ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA portfolio right now.

The deal will partner Tempus with AstraZeneca and Pathos to build the world's largest multimodal oncology foundation, ... Analysts Can Provide a Catalyst for Tempus AI Stock in 2025.

Tempus AI Inc (NASDAQ: TEM) came ... Spruce Point cited several reasons, including account irregularities and eroding ties with key clients like AstraZeneca, for its bet against the Nasdaq listed ...

Tempus AI will receive $200 million in data licensing and model development fees from AstraZeneca. This amount almost exactly matches the amount of revenue the company generated in the fourth ...

The deal will partner Tempus with AstraZeneca and Pathos to build the world’s largest multimodal oncology foundation, worth $200 million over the next three years, exclusive of other revenue it ...